Biomedical device company Biotronik has received U.S. Food and Drug Administration (FDA) clearance to use its Iperia implantable cardioverter defibrillator (ICD) systems with MRI studies.
Biotronik's ProMRI technology enables patients with approved device systems to receive 1.5-tesla MRI scans without an exclusion zone, according to the company. The clearance for the ProMRI ICD family covers the Iperia DX ICD hybrid system and the Iperia DR-T leads in both DF-1 and DF4 configurations. Biotronik's ProMRI DX ICD also is included, Biotronik said.
